Lilly’s Ceclor
Executive Summary
Lilly oral cephalosporin product is showing "sales growth in the mid-teens" percentage range in 1990, Exec VP and Pharmaceutical Division President Eugene Step told Mabon Nugent research conference Dec. 5. Eleven-year old oral cephalosporin cefaclor loses patent exclusivity in mid-1992, but Step said generic competitors "may be in for a bit of a surprise" because cefaclor's "complex production process" may keep generic companies from seeking to market product. He noted that, outside the U.S. where no patent protection exists, Lilly knows of no generic Ceclor on the market or in development. Lilly's H[2] antagonist Axid (nizatidine) and Humatrope (somatropin) human growth hormone are both growing in sales "well above 50% this year," Step said, with Humatrope expected to top $100 mil. in sales, the eighth Lilly drug to exceed that milestone. Carbacephem broad spectrum antibiotic loracarbef NDA is "on track at FDA," he noted.
You may also be interested in...
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.